Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015691 | 0.90 | ALDH1A1 (0.80) | ALDH1A1EPHX1SMN1; SMN2LMNAHPGD | |
| SCHEMBL15906221 | 0.82 | EPHX1 (0.50) | ALDH1A1RAB9AEPHX1NPC1SMN1; SMN2 | |
| SCHEMBL18536761 | 0.82 | ALDH1A1 (0.88) | ALDH1A1RAB9AEPHX1SMN1; SMN2HPGD | |
| SCHEMBL10132085 | 0.81 | SMN1; SMN2 (0.65) | ALDH1A1EPHX1SMN1; SMN2LMNAHPGD | |
| SCHEMBL24556901 | 0.81 | ALDH1A1 (0.67) | ALDH1A1EPHX1SMN1; SMN2LMNAGAA | |
| SCHEMBL15906214 | 0.81 | SMYD3 (0.54) | RAB9AEPHX1NPC1SMN1; SMN2GAA | |
| SCHEMBL13649892 | 0.81 | SMYD3 (0.54) | RAB9AEPHX1NPC1SMN1; SMN2GAA | |
| SCHEMBL20650992 | 0.80 | ALDH1A1 (1.00) | ALDH1A1EPHX1SMN1; SMN2HPGD | |
| SCHEMBL22061771 | 0.80 | ALDH1A1 (1.00) | ALDH1A1EPHX1SMN1; SMN2HPGD | |
| SCHEMBL10078357 | 0.80 | ALDH1A1 (1.00) | ALDH1A1EPHX1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | ALDH1A1 750/4885RAB9A 2410/4885EPHX1 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.